New study tracks muscle decline in rare disease to guide future treatments

NCT ID NCT03842878

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study followed 52 people with limb-girdle muscular dystrophy 2I (LGMD2I) for up to two years to learn more about how the disease changes over time. Researchers measured walking ability, muscle strength, heart function, and daily activities. The goal was to better understand the disease's natural course, which can help design future treatment trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LGMD2I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal recessive limb-girdle muscular dystrophy type 2I

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dr Tanya Stojkovic

    Paris, 75013, France

  • Pr John Vissing

    Copenhagen, DK-2100, Denmark

  • Pr Volker Straub

    Newcastle, NE1 3BZ, United Kingdom